- Oral presentation
- Open Access
MRI reveals hemodynamic changes with acute maternal hyperoxygenation in human fetuses with and without congenital heart disease
Journal of Cardiovascular Magnetic Resonance volume 17, Article number: O55 (2015)
Maternal hyperoxygenation (MH) has been used for intrauterine growth restriction and proposed as a way to improve ventricular growth in the setting of congenital heart disease (CHD)[1, 2]. Fetal lamb experiments reveal increases in the SaO2 of umbilical venous (UV) blood and a reduction in pulmonary vascular resistance during MH . Doppler suggests that MH increases the human fetal pulmonary blood flow (PBF) . The combination of fetal phase contrast (PC) MRI and MR oximetry using T2 mapping offers the potential for a comprehensive hemodynamic assessment of late gestation fetal circulation . We investigated the physiologic impact of MH in human fetuses with and without CHD using MRI to explore the potential therapeutic benefits of chronic MH.
We examined 17 normal human fetuses [mean gestational age (GA) of 37.3 wks; SD ± 1 wk] and 20 fetuses with CHD (mean GA of 36.2 wks; SD ± 1 wk) on a 1.5T system (Siemens Avanto, Erlangen, Germany) after hospital IRB approval. Flows were measured in major fetal vessels using PC MRI and indexed to fetal weight along with T2 of UV blood according to our previously published technique [5, 6]. According to the Luz-Meiboom equation  the T2 relaxation of blood is proportional to its O2 saturation. The measurements were repeated during MH (12 L/min of O2 via a non-rebreather mask, FiO2 ∼70%). Results were compared using Student's t-test, with results with p-value ≤ 0.05 considered statistically significant.
At baseline, the UV T2 was lower in CHD fetuses than in normals. Although UV T2 did not change significantly with MH in normals, we observed a significant increase in UV T2 in CHD fetuses with MH (p=0.01, Fig. 1, Table 1). Both groups showed a statistically significant increase in PBF during MH but was more dramatic in CHD fetuses (p=0.005). While there was a significant reduction in ductus arteriosus (DA) flow in CHD fetuses during MH (p=0.04), this was not present in normals. There was no significant difference in blood flow in any of the other major vessels.
The reason for lower O2 saturations in the UV of fetuses with CHD is uncertain, but may reflect abnormal placental and/or fetal cardiovascular function. The lower position of UV blood saturation on the O2 dissociation curve of hemoglobin may explain the higher uptake of O2 from maternal plasma in CHD fetuses. The expected increase in PBF with MH was observed in both groups. This increase in PBF also explains the lower DA flow in CHD fetuses with MH who had significantly higher DA flow compared to normal at baseline (p=0.002). This study suggests that fetal MR can be used to assess hemodynamic changes resulting from MH and could provide useful additional fetal monitoring when MH is being used for therapy.
This work was performed with support from the Labatt Family Heart Centre Innovations Fund.
Say,et al: Cochrane Database Syst. Rev. 2003
Kohl : Ped Cardiol. 2010
Rudolph,et al: Wiley-Blackwell. 2009
Rasanen,et al: Circ. 1998
Sun,et al: ISUOG. 2014, Barcelona, Abstract
Prsa,et al: Circ Cardiovasc Imag. 2014
Luz,et al: J Chem Physics. 1963
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Porayette, P., Sun, L., Jaeggi, E. et al. MRI reveals hemodynamic changes with acute maternal hyperoxygenation in human fetuses with and without congenital heart disease. J Cardiovasc Magn Reson 17 (Suppl 1), O55 (2015). https://doi.org/10.1186/1532-429X-17-S1-O55
- Congenital Heart Disease
- Pulmonary Blood Flow
- Human Fetus
- Fetal Monitoring
- Potential Therapeutic Benefit